Looking to win back investor confidence, BioMarin preps for its ‘largest launch’
BioMarin is ready to launch the first drug to treat achondroplasia, the most common form of dwarfism, in Voxzogo – it just needs an FDA greenlight.
The US commercial team is planning for Voxzogo’s launch at the end of the year with an “experienced” sales force already in place, BioMarin execs told analysts in its quarterly call this week. The biopharma is also working with the FDA on late-stage labeling and post-marketing requirements.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 129,600+ biopharma pros reading Endpoints daily — and it's free.